Xeomin (incobotulinumtoxinA) and Daxxify (daxibotulinumtoxinA) are both FDA-approved botulinum toxin type A products used for the temporary improvement in.
Last reviewed: 2026-05-06
14 min read
Ready to explore your options in Istanbul?
Connect with our coordination team for a personalised treatment plan, verified provider matching, and travel logistics support.
Content is educational and planning-oriented. It does not replace diagnosis, treatment, or personalized medical advice from a licensed healthcare professional. Outcomes vary by individual case.
Xeomin and Daxxify are FDA-approved botulinum toxin type A products with distinct formulation differences that affect duration and treatment considerations.
Xeomin contains no accessory proteins, while Daxxify uses proprietary peptide technology that may extend duration of effect.
Botulinum toxin products are not interchangeable due to different unit measurements and formulation characteristics.
Both products carry FDA boxed warnings for distant spread of toxin effect; immediate medical attention is needed for swallowing or breathing difficulties.
Individual results vary based on anatomy, muscle strength, injection technique, and metabolism.
Educational information only
This content is general education and does not replace evaluation by a licensed clinician. If you have symptoms, complications, or urgent concerns, seek in-person medical care.
Core Context — Understanding Botulinum Toxin Type A
Xeomin (incobotulinumtoxinA) and Daxxify (daxibotulinumtoxinA) are both FDA-approved botulinum toxin type A products used for the temporary improvement in the appearance of facial wrinkles. While they share the same fundamental mechanism of action, their formulation differences create distinct clinical profiles that may influence treatment decisions.
For foundational context on botulinum toxin treatments broadly, explore the Botulinum Toxin Resource Hub to understand how these products fit within the broader landscape of injectable treatments.
What Are Xeomin and Daxxify?
Xeomin is often referred to as the "naked" botulinum toxin because it contains no accessory proteins—only the active neurotoxin component. This highly purified formulation may offer advantages for some patients, particularly those concerned about potential antibody development over time. The product received FDA approval for aesthetic use and has been widely studied in clinical trials for glabellar lines, horizontal forehead lines, and lateral canthal lines S1.
Daxxify represents a newer generation of botulinum toxin formulations, utilizing proprietary peptide technology (RTP004) that enhances molecular stability. This peptide wrapper helps maintain the toxin's structure longer at the injection site, which may contribute to extended duration of effect for some patients. The FDA approved Daxxify for glabellar lines, and clinical trials have explored its application in other facial areas.
Formulation Differences
The purified profile of Xeomin contrasts with Daxxify's peptide-enhanced approach. These distinct formulation strategies may influence treatment selection based on individual patient factors and treatment goals.
How Neuromodulators Work
Both Xeomin and Daxxify function by inhibiting neuromuscular transmission through a precise mechanism. The active component cleaves the SNARE protein complex, which is essential for acetylcholine release at the neuromuscular junction S7. Without acetylcholine release, the targeted muscle cannot contract, resulting in temporary muscle relaxation and reduced wrinkle appearance in the overlying skin.
The effects of treatment typically become noticeable within several days, with peak effect usually occurring around two to four weeks post-injection. Duration varies considerably among individuals and depends on factors including the treatment area, dosage, injection technique, individual metabolism, and muscle strength. Most clinical trials measure duration based on return to baseline muscle activity rather than complete loss of effect.
The Botulinum Toxin Product Landscape
Five FDA-approved botulinum toxin type A products are available in the United States: onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), prabotulinumtoxinA (Jeuveau), and daxibotulinumtoxinA (Daxxify). Each product has unique characteristics regarding unit potency, formulation, and recommended dosing S7.
Products Are Not Interchangeable
Botulinum toxin products should never be considered interchangeable. Different products have different unit standardization systems, meaning that a specific number of units of one product does not equate to the same number of units of another product. Dosing conversions between products are not standardized and should only be performed by experienced practitioners who understand the specific characteristics of each formulation S7.
Understanding these differences is essential for patients who have previously received treatment with one product and are considering a switch to another. Practitioners must evaluate each patient's individual response history and adjust dosing accordingly rather than applying direct unit conversions.
Decision Criteria — Comparing Xeomin and Daxxify
Duration of Effect
The most significant clinical difference between Xeomin and Daxxify lies in their typical duration of effect. Xeomin generally provides results lasting three to four months, consistent with traditional botulinum toxin formulations S1. This duration aligns with what has been observed in clinical trials for other non-peptide-enhanced botulinum toxin products.
Daxxify has demonstrated notably longer duration in clinical studies, with median effect lasting 24 to 27 weeks according to pivotal trial data S5. This extended duration may reduce the frequency of maintenance treatments for some patients. However, individual responses can vary significantly, and not all patients experience the full duration observed in clinical trials.
Individual Variation
Duration of effect depends on multiple factors including the treatment area, dosage, injection technique, individual anatomy, muscle strength, and metabolism. Some patients may find that Daxxify lasts longer than Xeomin, while others may experience similar duration with both products. Discussing realistic expectations with your provider is essential before treatment.
Efficacy Profiles
Clinical trial data supports effective treatment outcomes for both products. For Xeomin, pivotal Phase 3 trials demonstrated treatment success rates of 88.6% for glabellar frown lines and 92% for horizontal forehead lines at Day 30 compared to 0% for placebo S1. These results were comparable to historical data for other botulinum toxin type A products, confirming Xeomin's efficacy in clinical settings.
Daxxify's pivotal SAKURA 1 and 2 trials established treatment success rates of 74% at week 4 for glabellar lines S6. The SAKURA 3 open-label safety study, which enrolled 2,691 subjects receiving 3,830 treatments, provided additional real-world evidence supporting the product's efficacy profile S3. Treatment success was defined using validated clinical scales assessing wrinkle severity at rest and maximum contraction.
For patients considering these treatments, efficacy should be evaluated alongside other factors including duration, cost considerations, and individual treatment goals. What works well for one person may not produce identical results for another.
Formulation Considerations
The fundamental difference between Xeomin and Daxxify lies in their formulation chemistry. Xeomin's "naked" toxin design removes accessory proteins that are present in some other formulations. This purification process may reduce the antigenic load, potentially lowering the risk of antibody development in some patients. The clinical significance of this difference continues to be studied S1.
Daxxify's peptide technology (RTP004) wraps the active toxin in a proprietary peptide designed to enhance stability and prolong the time the toxin remains active at the injection site S5. This formulation approach is unique among FDA-approved botulinum toxin products and contributes to the extended duration observed in clinical trials.
Treatment Protocol Differences
Treatment protocols vary between products due to their different formulations and unit characteristics. Dosing recommendations are specific to each product and should not be interchanged without proper understanding of the respective potencies S7. Injection site recommendations follow similar anatomical guidelines, but exact unit placement may vary based on individual patient anatomy and treatment goals.
Treatment intervals naturally differ based on product duration characteristics. Patients using Xeomin typically schedule maintenance treatments every three to four months, while those using Daxxify may extend intervals to six months or longer depending on individual response.
Source-Backed Facts — Evidence from Clinical Research
Xeomin Clinical Evidence
Clinical evidence for Xeomin comes from multiple Phase 3 trials demonstrating consistent efficacy across facial treatment areas. In pivotal studies for glabellar lines, treatment success rates reached 88.6% at Day 30 compared to 0% in placebo groups S1. Similar trials for horizontal forehead lines showed 92% success rates, while lateral canthal lines (crow's feet) demonstrated 81.3% treatment success.
Head-to-head trials comparing Xeomin with onabotulinumtoxinA have confirmed comparable efficacy between these formulations. These comparative studies demonstrate that Xeomin produces results consistent with established botulinum toxin products when used at appropriate doses.
Safety data from clinical trials and real-world use supports a favorable profile for Xeomin. The most commonly reported adverse reaction involves injection site bruising, which occurred in approximately 2% of patients in clinical trials S1. Other reported effects are generally mild and transient, resolving without intervention in most cases.
Daxxify Clinical Evidence
The Daxxify clinical program includes several pivotal studies establishing its efficacy and safety profile. The SAKURA 1 and 2 trials were randomized, double-blind, placebo-controlled studies that established FDA approval for glabellar line treatment S6. These trials demonstrated statistically significant improvements compared to placebo at all measured timepoints.
The SAKURA 3 open-label safety study represents one of the largest botulinum toxin safety datasets, with 2,691 subjects receiving 3,830 treatments over multiple treatment cycles S3. This extensive dataset provides confidence in the product's safety profile across repeated treatments. Treatment success rates of 74% at week 4 were consistent with the pivotal trial findings.
Duration data from these studies revealed median responses of 24 to 27 weeks, significantly longer than the 3-4 months typically observed with traditional formulations S5. This extended duration was a primary factor driving FDA approval and distinguishes Daxxify from other available products.
Safety Profile Comparison
Both products share the fundamental safety considerations associated with botulinum toxin type A products. Common adverse events for Xeomin include injection site reactions such as bruising, redness, and temporary discomfort. Headache occurs in a minority of patients and typically resolves within 24-48 hours.
Daxxify's safety data from the SAKURA 3 study showed headache occurring in 5.9% of treatments, injection site pain in 3.9%, and erythema in 3.3% S3. Eyelid ptosis—a drooping of the upper eyelid—occurred in only 0.9% of treatments, comparable to rates reported for other botulinum toxin products.
Risk Controls — Safety Considerations and Contraindications
FDA Boxed Warning
Both Xeomin and Daxxify carry FDA boxed warnings regarding the distant spread of toxin effect. In rare cases, the effects of botulinum toxin may extend beyond the injection site, potentially causing symptoms including swallowing difficulties, breathing problems, and muscle weakness S7. These effects can occur hours to weeks after injection and have been reported in patients receiving treatment for various approved indications.
Seek Immediate Medical Attention
Contact emergency services or go to the nearest emergency department if you experience any of the following after treatment: difficulty speaking, swallowing, or breathing; muscle weakness spreading beyond the treatment area; vision problems or drooping eyelids; loss of bladder control; or any signs of an allergic reaction. Early intervention is important for managing potential complications.
The boxed warning applies to all botulinum toxin products regardless of formulation. While serious adverse events are rare, understanding the warning signs helps ensure prompt medical attention when needed.
Common Side Effects and Management
Injection site reactions represent the most frequently observed side effects with both products. These typically include temporary bruising, redness, swelling, and minor discomfort at the injection points. Most injection site reactions resolve spontaneously within several days without intervention.
Headache occurs in a small percentage of patients following treatment and usually resolves within 24-48 hours. Over-the-counter pain relievers may be used for symptomatic relief unless contraindicated by other medical conditions. Staying well-hydrated and avoiding alcohol for 24 hours before and after treatment may help reduce headache risk.
Eyelid ptosis (drooping) can occur when the toxin migrates to muscles controlling eyelid position. Experienced practitioners minimize this risk through proper injection technique, appropriate dosing, and avoiding treatment near the brow in patients with heavy brow positioning. When ptosis occurs, it typically resolves as the toxin effect diminishes over weeks.
Absolute and Relative Contraindications
Treatment with botulinum toxin products is contraindicated in several situations. Hypersensitivity to any product component—including the active toxin, human albumin, or other formulation ingredients—precludes treatment. Active infection at or near the planned injection site also contraindicates treatment until the infection resolves.
Patients with underlying neuromuscular conditions require particular caution and thorough medical evaluation before treatment. Conditions including myasthenia gravis, Lambert-Eaton syndrome, and amyotrophic lateral sclerosis (ALS) may increase susceptibility to the systemic effects of botulinum toxin. Treatment in these populations should only occur under specialist supervision.
Pregnancy and Breastfeeding
Botulinum toxin products are contraindicated during pregnancy and breastfeeding. If you are pregnant, planning pregnancy, or breastfeeding, discuss this with your provider before considering treatment. The effects on fetal development and infant health have not been established.
Drug Interactions and Precautions
Several medications may interact with botulinum toxin effects or increase bleeding risk at injection sites. Aminoglycoside antibiotics and other medications affecting neuromuscular transmission may potentiate the effects of botulinum toxin, potentially increasing the risk of systemic effects. Anticholinergic medications may have altered effects when combined with botulinum toxin treatment.
Patients should provide a complete medication and supplement history to their provider before treatment. This includes prescription medications, over-the-counter drugs, herbal supplements, and any previous botulinum toxin treatments. The timing of previous treatments is particularly important when switching between products or planning repeat treatments.
Action Checklist — What Patients Should Discuss with Providers
For Injectable Treatments Overview, including Xeomin and Daxxify, patients should ensure thorough consultation with qualified providers before proceeding.
Pre-Treatment Consultation Questions
Before committing to treatment, consider discussing several important topics with your provider. Ask about their training and experience with both Xeomin and Daxxify specifically—not all practitioners have equal experience with all available products. Inquire about how they determine appropriate dosing and which product they would recommend for your specific goals.
Find a Qualified Provider who has documented experience with botulinum toxin treatments and can discuss the specific products they recommend for your situation.
A thorough consultation should include discussion of your medical history, current medications, previous experiences with botulinum toxin, realistic outcome expectations, and potential risks specific to your situation. Take time to evaluate the provider's communication style and whether they address your concerns adequately.
Request to see before-and-after photographs of previous patients with similar treatment goals. While individual results vary, reviewing a provider's work helps establish realistic expectations and assess their aesthetic approach.
Assessment Criteria
A proper treatment assessment should evaluate your facial anatomy, including muscle strength and pattern, skin condition, and specific areas of concern. The provider should discuss your treatment goals in detail and explain what results are realistically achievable with botulinum toxin treatment.
Document your baseline facial expression and movement patterns before treatment. This baseline helps both you and your provider assess treatment results at follow-up appointments. Taking photographs under standardized conditions can provide objective documentation of changes over time.
Post-Treatment Care
Following treatment, most providers recommend avoiding strenuous exercise, alcohol, and excessive sun or heat exposure for 24 hours. Staying upright for several hours after treatment helps prevent the toxin from migrating from the intended treatment area. Avoid rubbing or massaging the treated areas.
Monitor for any unusual symptoms in the days and weeks following treatment. While most side effects are mild and transient, persistent or unusual symptoms should prompt contact with your provider. Schedule follow-up appointments as recommended to assess results and plan any touch-up treatments.
Travel-Specific Considerations
If you are traveling to receive treatment, plan your timeline carefully. Allow time for an initial consultation before treatment day, and consider scheduling follow-up before departing if possible. Request written documentation of your treatment including the product used, dosage, injection sites, and date of treatment.
Accredited Facilities that meet international standards can provide additional confidence in the safety and quality of your treatment environment. Verify facility accreditation and provider credentials before booking.
Travel Planning
If traveling internationally for treatment, consider the logistics of potential complications occurring after you return home. Know the signs requiring medical attention, understand your provider's follow-up protocols, and have a plan for communicating with your treatment team remotely if needed. Medical Travel Coordination can help organize these logistics.
Carry documentation of your treatment when crossing borders, as some countries may have questions about medical treatments. Having product information readily available helps address any inquiries and supports continuity of care if you seek future treatments in another country.
